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a b s t r a c t
Nef plays a major role in HIV-1 pathogenicity. We studied HIV-1 subtype C infected individuals in acute/
early (n¼120) or chronic (n¼207) infection to investigate the relationship between Nef-mediated CD4/
HLA-I down-regulation activities and disease progression, and the inﬂuence of immune-driven sequence
variation on these Nef functions. A single Nef sequence per individual was cloned into an expression
plasmid, followed by transfection of a T cell line and measurement of CD4 and HLA-I expression. In early
infection, a trend of higher CD4 down-regulation ability correlating with higher viral load set point was
observed (r¼0.19, p¼0.05), and higher HLA-I down-regulation activity was signiﬁcantly associated with
faster rate of CD4 decline (p¼0.02). HLA-I down-regulation function correlated inversely with the
number HLA-associated polymorphisms previously associated with reversion in the absence of the
selecting HLA allele (r¼0.21, p¼0.0002). These data support consideration of certain Nef regions in
HIV-1 vaccine strategies designed to attenuate the infection course.
& 2014 Elsevier Inc. All rights reserved.
Introduction
HIV-1 Nef is a small accessory protein that plays a major role in
viral replication and pathogenesis (Foster et al., 2011). Nef displays
multiple functions in vitro, including down-regulation of cell-surface
CD4 (to enhance viral spread and possibly evade antibody-dependent
cell-mediated cytotoxicity of infected cells), down-regulation of HLA
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class I (HLA-I) A and B molecules (to evade CD8þ T cell responses),
activation of T cells and CD4-independent enhancement of virion
infectivity (Foster and Garcia, 2008; Veillette et al., 2014). The relative
importance of these Nef activities in vivo remain incompletely under-
stood, although some studies suggest that Nef-mediated CD4 down-
regulation, enhancement of infectivity, and one or more unknown Nef
functions represent major pathogenic contributors (Iafrate et al., 2000;
Watkins et al., 2013).
Nef's inﬂuence on HIV-1 pathogenesis is clearly demonstrated
by an attenuated disease course in individuals infected with HIV-1
harbouring gross genetic Nef defects (Deacon et al., 1995; Kestler
et al., 1991; Kirchhoff et al., 1995). However, more subtle,
naturally-occurring variation in Nef may also inﬂuence disease
outcomes. For example, Nef proteins derived from HIV-1 subtype B
infected elite controllers displayed relative functional impairments
compared to those from progressors in the absence of major
genetic defects (Mwimanzi et al., 2011c, 2013). Studies linking
Nef function and disease outcomes in HIV-1 subtype C, the
predominant subtype of the HIV pandemic, are however lacking.
Nef is also a highly immunogenic protein (Lichterfeld et al.,
2004). Cross-sectional studies have shown that the overall breadth
of Nef-speciﬁc CD8þ T cell responses does not correlate with viral
control (Kiepiela et al., 2007) and in some studies a higher
magnitude of these responses correlated with higher viral loads
(Novitsky et al., 2003; Radebe et al., 2011). Nevertheless, the
observed associations between lower viral loads and CD8þ T cell
targeting of certain Nef epitopes in humans (Adland et al., 2013)
and non-human primate models (Budde et al., 2012; Mudd et al.,
2012), suggests that CD8þ T cell responses to speciﬁc Nef regions
may be beneﬁcial.
There is also somewhat limited evidence that immune-driven
escape mutations can impair Nef function. Two HLA-Bn35-asso-
ciated CD8þ T cell escape mutations in a conserved proline-rich
region of Nef impaired Nef-mediated HLA class I down-regulation
and virus replication when occurring in combination (Mwimanzi
et al., 2011a; Ueno et al., 2008). Accumulation of novel HLA-Bn57-
associated polymorphisms largely unique to elite controllers was
associated with reduced Nef function in these individuals
(Mwimanzi et al., 2013). Furthermore, a recent study predicted
that over 50% of HLA-associated Nef polymorphisms would revert
on transmission to an HLA-mismatched recipient, supporting
biologically-relevant ﬁtness costs of certain immune-driven muta-
tions in Nef (Adland et al., 2013). Identiﬁcation of immune-driven
Nef mutations inﬂuencing its pathogenic functions could therefore
reveal regions of potential relevance for inclusion in an HIV-1
vaccine designed to attenuate the infection course (Allen and
Altfeld, 2008). Thus, studies to investigate this are warranted.
Also important to vaccine design is the identiﬁcation of speciﬁc
features of viruses that are transmitted successfully (i.e. under-
standing the transmission bottleneck). Transmitted/early viruses
tend to exhibit particular Env characteristics, including shorter
variable loops with fewer glycosylation sites (Derdeyn et al., 2004;
Sagar, 2010) and near-exclusive CCR5 co-receptor usage (Sagar,
2010); however, there is little knowledge regarding whether Nef
characteristics of early viruses may differ from those from later
infection stages (Noviello et al., 2007). Similarly, envelope length
and number of glycosylation sites may increase during the infec-
tion course (Sagar et al., 2006) (though this remains somewhat
controversial (Novitsky et al., 2009a)); however, few studies have
examined early sequence and/or functional changes in Nef in large
numbers of patients, particularly in a subtype C context (Brumme
et al., 2008; Kuang et al., 2014; Noviello et al., 2007).
To address these knowledge gaps, we assessed two Nef func-
tions implicated in pathogenesis – down-regulation of CD4 and
HLA-I – in clonal plasma HIV RNA-derived Nef sequences isolated
from untreated HIV-1 subtype C infected individuals from
different disease stages. We studied a single representative Nef
clone from each patient, including 120 individuals in early infec-
tion (of whom a subset of 68 individuals were additionally
characterised for Nef function one year later), and an independent
group of 207 individuals in the chronic phase of infection. We
investigated (i) the relationship between Nef function in early
infection and subsequent rate of HIV-1 disease progression, and
(ii) the relationship between Nef function and sequence, in
particular immune-driven HLA-associated Nef mutations. In addi-
tion, as an exploratory analysis we assessed differences in the
genetic characteristics of Nef in early and chronic infection as well
as changes in Nef function and sequence over the ﬁrst year of
infection.
Results
Nef clones: function and expression
Nef-mediated CD4 and HLA-I down-regulation were measured
for 395 Nef clones from 327 individuals (120 with acute/early
infection, for whom 68 also had a follow-up clone at 1 year post-
infection, as well as 207 with chronic infection) in a CEM T cell line
expressing HLA-An02:01. It should be noted that we previously
observed an excellent correlation between the relative ability of
Nef clones to down-regulate HLA-An02 and HLA-Bn07, justifying
that HLA-An02 down-regulation is in general representative of
HLA-I down-regulation (Mann et al., 2013). The functions of
patient-derived Nef sequences were expressed relative to that of
the subtype B reference Nef sequence SF2, which represented
100% activity (Supplementary Table 2, representative ﬂow plots in
Fig. 1). Overall, patient-derived Nef clones showed a median CD4
down-regulation ability of 96% (IQR, 77.6 to 99.7%) and a median
HLA-I down-regulation ability of 76% (IQR, 53.4 to 87%) compared
to the control subtype B SF2 strain. A minority of Nef clones
(n¼47, 12%) was poorly functional (o45% for both Nef functions).
To conﬁrm their Nef protein expression, Western blots were
performed on this subset as well a randomly-selected set of 78
Nef clones that displayed 450% CD4 or HLA-I down-regulation
ability relative to SF2 (indicating that Nef was expressed). Of the
47 poorly functional clones, 41 were not readily detectable by
Western blot using polyclonal anti-Nef sera from rabbit or sheep
(deﬁned as o30% of SF2 control, Supplementary Table 2), while
8 of the 78 functional clones were below this threshold of
detection. Since we cannot exclude the possibility that Nef clones
with poor expression and function are attributable to cloning or
other in vitro artifact, we excluded these 41 isolates from all
further analyses. This left a total of 354 Nef clones for analysis:
107 from acute/early infection, 61 from 1 year post-infection
(including 56 paired clones at baseline and 1 year post-infection),
and 186 from chronic infection. The Western blot band intensities
of the remaining Nef clones did not correlate signiﬁcantly with
CD4 down-regulation (Spearman's, r¼0.16 and p¼0.15) or HLA-I
down-regulation (Spearman's, r¼0.18 and p¼0.1) (Supplementary
Fig. 1).
Similar Nef function and sequence in different cohorts and
laboratories
Our Nef sequences from acute/early infection were derived
from various cohort and clinical studies in Botswana (Tshedimoso
[n¼27]) and South Africa (HPP acute infection [n¼33] and TRAPS
[n¼47] cohorts). In addition, samples from the HPP acute infection
cohort and Tshedimoso cohort were assayed in the HIV Pathogen-
esis Programme Laboratory at the University of KwaZulu-Natal
while those from the TRAPS cohort were assayed in the HIV/AIDS
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Molecular Epidemiology Laboratory at Simon Fraser University.
As such, we conﬁrmed that there were no signiﬁcant cohort- or
laboratory-speciﬁc biases in Nef function before pooling data for
analysis. Both Nef-mediated CD4 down-regulation and HLA-I
down-regulation activities of Nef clones from recent infection
were comparable across cohorts (Kruskal–Wallis, p40.2) and
laboratories (Mann–Whitney p40.2) (Fig. 2A and B). In addition,
no gross clustering of Nef clones by site was observed in a
combined phylogeny (Fig. 2C), and no signiﬁcant differences in
the average pairwise distance between patient Nef clone and
published Nef consensus C sequence were observed by cohort
(Kruskal–Wallis, p¼0.84). Thus, all Nef sequences from acute/early
infection were combined in subsequent analyses.
Association of Nef-mediated CD4 and HLA-I down-regulation function
in acute/early infection with subsequent disease progression
To assess the relationship between Nef function in acute/early
infection and subsequent disease progression, CD4 and HLA-I
down-regulation abilities of Nef clones from the earliest time-
point post-infection were correlated with subsequent viral load set
point and rate of CD4 decline. Viral load set point (median of
4.4 log10 copies/ml; IQR, 3.7–5 log10 copies/ml) and rate of CD4
decline (median of 4 cells/mm3 per month; IQR, 10 to
1 cells/mm3 per month) were calculated for 102 and 107 indivi-
duals, respectively. Rate of CD4 decline was calculated over a
median treatment-free follow-up of 672 days; IQR, 346–1304 days.
A trend of increased Nef-mediated CD4 down-regulation func-
tion at baseline correlating with higher viral load set point was
observed (Spearman's, r¼0.19 and p¼0.05), but no relationship
was observed between HLA-I down-regulation and viral load set
point (Spearman's, r¼0.14 and p¼0.18) (Fig. 3A and B). Further-
more, both CD4 and HLA-I down-regulation functions were
associated inversely with rate of CD4 decline, the latter signiﬁ-
cantly so (Spearman's, r¼0.18, p¼0.07 and r¼0.24, p¼0.01
respectively). However, baseline CD4 count and length of follow-
up time also signiﬁcantly correlated with CD4 decline in our
cohorts (Spearman's, r¼0.25, p¼0.01 and r¼0.31, p¼0.001
respectively); therefore, a multiple linear regression was per-
formed to assess the relationship between Nef function and rate
of CD4 decline while controlling for these potential confounders
(see Methods and Table 1). After accounting for these and other
baseline parameters such as viral load, the association between
higher Nef-mediated HLA-I down-regulation and faster rate of CD4
decline remained statistically signiﬁcant (p¼0.02) (Table 1). In a
multivariate analysis additionally adjusting for cohort site, HLA-I
down-regulation still remained signiﬁcantly associated with rate
of CD4 decline (p¼0.048; data not shown).
Sequence-function analysis part 1: lack of genetic differences between
acute/early and chronic Nef sequences
We next wished to identify sequence determinants of Nef
function using a maximally-powered dataset. To do this, we ﬁrst
Fig. 1. Nef-mediated down-regulation of cell-surface CD4 and HLA-I. Representative ﬂow cytometry plots show cell-surface expression of CD4 or HLA-I (y axis) in cells
transfected with empty plasmid (Δ Nef, negative control), wild-type Nef plasmid (SF2 Nef, positive control), and plasmid expressing a patient-derived Nef. Green ﬂuorescent
protein (GFP) expression (x axis) was used as a marker of cells transfected with plasmids.
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compared Nef sequences from acute/early (n¼107) and chronic
infection (n¼186) to investigate whether the former possess
features that distinguish them from the latter and whether
combining Nef sequence data across different disease stages for
our sequence-function analysis would introduce major biases. No
signiﬁcant differences in Nef sequence length (Mann–Whitney,
p¼0.35) and no signiﬁcant differences in the frequency of the
predominant (consensus) amino acids were observed at any Nef
codon between clones collected during acute/early and chronic
infection (Fisher's exact test, p40.09; data not shown). Moreover,
acute/early and chronic sequences were interspersed in a
phylogenetic tree (Fig. 4). There were, however, marginally greater
pairwise distances from Nef consensus C sequence in early infec-
tion clones (median 11.9% [IQR, 10.6–13.9%] ) compared to 11.1% for
chronic infection clones [IQR, 10–12.6%], Mann–Whitney,
p¼0.007). In summary, although we cannot exclude the possibility
that there is some transmission bottleneck in the Nef gene
resulting in increased transmission of non-consensus sequences,
we found overall that there were no major differences between
Nef sequences from acute/early and chronic infection. Given the
lack of major differences between Nef sequences from acute/early
and later infection and phylogenetic inter-mixing of these groups
Fig. 2. Functional and sequence comparison of acute/early infection Nef clones derived from different cohorts and assayed in different laboratories. Panel A and B: graphs
show no signiﬁcant differences in CD4 (A) and HLA-I (B) down-regulation function between Nef clones derived from the HPP (green), Tshedimoso (blue) and TRAPS (red)
cohorts, as tested by Kruskal–Wallis (KW). No signiﬁcant differences in either Nef function were found between Nef clones constructed and assayed in different laboratories
(HPP and Tsedimoso versus TRAPS) using the Mann–Whitney U test (p40.2). Bars indicate the median and whiskers represent the inter-quartile range. Panel C: the
maximum-likelihood phylogenetic tree shows good intermixing of Nef clonal sequences from HPP (green), Tshedimoso (blue) and TRAPS (red) cohorts. The reference 2004
consensus C Nef sequence from the Los Alamos HIV sequence database is highlighted in orange.
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of sequences, we combined these into a single dataset to increase
power. Therefore, subsequent sequence-function analyses were
performed on a set of n¼298 Nef clones from unique patients as
follows: 107 from acute/early infection, 5 from 1 year post-
infection and 186 from chronic infection (the acute/early sequence
was used in the event where both acute/early and 1 year post-
infection sequences were available for the same individual).
Sequence-function analysis part 2: Nef amino acids associated with
increased or decreased HLA-I down-regulation function
A Nef sequence-function analysis for CD4 down-regulation
identiﬁed no Nef amino acids signiﬁcantly associated with varia-
tions in this Nef function. However, a similar analysis for HLA-I
down-regulation identiﬁed 31 amino acid variants at 22 different
Fig. 3. Relationship between Nef functions in acute/early infection and markers of disease progression. Panel A and B: A trend for a positive correlation between higher CD4
down-regulation in acute/early infection and subsequently higher viral load set point is shown (A), while no signiﬁcant relationship was observed between HLA-I down-
regulation and viral load set point (B) (n¼102). Panel C and D: associations between faster rate of CD4 decline and higher Nef-mediated CD4 (C) or HLA-I (D) down-
regulation in acute/early infection are shown, but this was statistically signiﬁcant for HLA-I down-regulation only (n¼107). Data in graphs C and D are restricted to 50 to
þ50 cells/mm3 per month, and thus do not include 5 outlier data points. Spearman's correlation was used to assess signiﬁcance of relationships.
Table 1
Multiple linear regression models investigating the relationship between rate of CD4 decline and Nef functions.
Variables
CD4 decline, model 1a
Variables
CD4 decline, model 2b
Co-efﬁcient p-value Co-efﬁcient p-value
CD4 down-regulation 7.7 0.12 HLA-I down-regulation 9.07 0.02
Square-root baseline CD4 1.02 o0.0001 Square-root baseline CD4 0.99 o0.0001
Follow-up time 0.01 o0.0001 Follow-up time 0.01 o0.0001
Log baseline viral load 0.87 0.32 Log baseline viral load 1.04 0.22
a Model for assessing relationship between CD4 decline and CD4 down-regulation: adjusted r2¼0.25, p¼o0.0001 and n¼102.
b Model for assessing relationship between CD4 decline and HLA-I down-regulation: adjusted r2¼0.28, p¼o0.0001 and n¼102.
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codons signiﬁcantly associated with this function (Table 2). Several
of these associations corroborated those identiﬁed in previous
studies: amino acid associations with differential HLA-I down-
regulation were identiﬁed at codons 3, 8, 9, 40, 102, 105, and 108
in a study of Nef subtypes A, B, C and D that included 74 subtype C
Nef clonal sequences analysed in the present study (Mann et al.,
2013) and similarly at codons 8 and 108 in HIV subtype B Nef
sequences (Mwimanzi et al., 2013). Of note, 3 codons identiﬁed in
this analysis, viz. 20, 62 and 64, are codons previously identiﬁed by
mutational analysis to play a role in HLA-I down-regulation (Akari et
al., 2000; Foster et al., 2011), while non-consensus variants 102H,
105R, 108D and 199Y, associated with reduced HLA-I down-regula-
tion (Table 2), are HLAnB44, Cn07:01, Bn44 and Bn18, and Cn16-
associated polymorphisms respectively (Supplementary Table 1). In
contrast, the consensus 108E, which is enriched in individuals with
HLA-Bn57:02 (Supplementary Table 1), is linked to higher HLA-I
down-regulation (Table 2). Together, these results suggest that HLA-
I-restricted CD8þ T cell responses could select polymorphisms
which impact Nef-mediated HLA-I down-regulation.
Sequence-function analysis part 3: increased numbers of HLA-
associated polymorphisms correlate with reduced HLA-I down-
regulation
To further explore the effect of HLA-associated polymorphisms on
Nef function, the number of such polymorphisms present in each
Nef sequence (deﬁned according to an independently-derived refer-
ence list of HLA-associated polymorphisms in HIV subtype C;
Supplementary Table 1) was correlated with Nef function (see
Methods). No signiﬁcant relationship between CD4 down-regulation
and number of polymorphisms was observed (Spearman's, r¼0.008
p¼0.89). However, a weak trend of inverse correlation between
number of HLA-associated Nef polymorphisms and HLA-I down-
regulation function was observed (Spearman's, r¼0.11 and
p¼0.06) (Fig. 5A).
Several HLA-associated mutations in Nef have been predicted to
revert upon transmission to a host lacking the original restricting HLA,
suggesting they may have ﬁtness costs (Adland et al., 2013). To
investigate the relationship between such “reverting” polymorphisms
and Nef HLA-I down-regulation function (n¼21 at 15 sites previously
associated with reversion, (Adland et al., 2013) and Supplementary
Table 1), we repeated our analysis considering only these polymorph-
isms. Of note, we observed a stronger inverse correlation with HLA-I
down-regulation function (Spearman's, r¼0.21 and p¼0.0002)
(Fig. 5B) compared to the original analysis undertaken on all HLA-
associated polymorphisms (Fig. 5A). Collectively, these results suggest
that HLA alleles can drive the selection of certain polymorphisms in
Nef that impair its function.
Sequence-function analysis part 4: polymorphisms associated with
HLA-Bn44, but not protective alleles Bn57, Bn58:01 and Bn81, correlate
with reduced HLA-I down-regulation
Previous studies have shown correlations between presence of
polymorphisms associated with protective HLA alleles and reduced
Gag-protease function (Brockman et al., 2007; Crawford et al., 2009;
Schneidewind et al., 2007;Wright et al., 2011), and between increasing
numbers of Bn57-associated Nef polymorphisms largely unique to
Fig. 4. Phylogenetic tree of HIV-1 subtype C Nef sequences from acute/early and
chronic infection. The maximum-likelihood phylogenetic tree shows good inter-
mixing of Nef clonal sequences derived from acute/early (red) and chronic (black)
infection. The reference 2004 consensus C Nef sequence from the Los Alamos HIV
sequence database is shown in blue.
Table 2
Amino acids (nZ5) associated with increased or decreased Nef HLA-I down-regulation
function.
Codona AAb Cons.c Relative Nef
function (%)d
No. of samplese p-value q-
value
With
AA
Without
AA
With
AA
Without
AA
3 N G 85.0 77.8 32 266 0.03 0.4
8 S S 77.8 84.7 256 35 0.02 0.3
9 S S 76.2 90.1 250 20 o0.0001 0.01
9 R S 85.5 77.1 11 259 0.007 0.2
12 G G 77.0 84.0 262 14 0.01 0.2
15 E A 84.9 77.1 47 251 0.03 0.3
20 M I 83.0 77.6 88 210 0.03 0.4
20 I I 76.9 81.1 179 119 0.04 0.4
23 T T 76.3 83.9 186 112 0.009 0.2
23 A T 83.9 76.8 106 192 0.01 0.2
40 Y H 74.8 82.0 126 172 0.002 0.1
40 H H 82.1 74.9 165 133 0.003 0.1
51 S N 64.7 79.3 9 289 0.02 0.3
62 E E 79.1 37.7 293 5 0.005 0.2
64 E E 80.2 71.1 253 45 0.01 0.3
64 D E 71.1 79.9 27 271 0.02 0.3
79 M M 79.1 44.6 293 5 0.02 0.3
102 H Y 71.8 79.9 45 253 0.01 0.2
105 R K 74.1 80.2 46 252 0.03 0.4
108 E E 82.7 74.2 159 139 0.001 0.1
108 D E 74.3 82.7 138 160 0.002 0.1
133 V V 80.2 68.6 265 33 0.005 0.2
146 V V 79.1 53.1 293 5 0.02 0.3
156 N A 89.1 78.1 6 292 0.02 0.3
161 D N 84.7 77.0 53 244 0.007 0.2
161 N N 76.9 83.2 235 62 0.02 0.3
178 K R 61.1 79.2 14 284 0.02 0.3
178 G R 84.9 77.9 40 258 0.04 0.4
188 N S 21.1 79.1 5 293 0.03 0.3
199 H H 79.4 47.8 290 8 0.002 0.1
199 Y H 51.8 79.3 7 291 0.005 0.2
a Numbered according to HXB2.
b Amino acid associated with increased or decreased HLA-I down-regulation
function.
c Cohort consensus amino acid at that particular codon.
d Median percentage HLA-I down-regulation function (expressed relative to
SF2 control) of Nef clones with and without the amino acid.
e Number of sequences with and without the amino acid. Amino acid totals
vary, as gaps in the alignment are considered missing data.
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elite controllers and reduced Nef CD4 down-regulation function
(Mwimanzi et al., 2013). Therefore, we investigated whether Nef
sequences harbouring polymorphisms associated with HIV subtype
C-speciﬁc protective HLA alleles Bn57, Bn58:01 and Bn81 (Kiepiela et al.,
2004) exhibited decreased Nef function. No relationship between the
numbers of these polymorphisms and either Nef function was
observed (Spearman's, p40.17; data not shown). In fact, the number
of polymorphisms speciﬁcally associated with HLA-Bn57 (83G, 83E,
108E, and 116N) was positively associated with HLA-I down-regulation
function (Spearman's, r¼0.12 and p¼0.04) (data not shown). This
result appeared to be driven by 108E, the consensus amino acid at
codon 108, which alone was associated with higher HLA-I down-
regulation (Mann–Whitney, p¼0.001).
HLA-Bn44:03, the most common subtype of Bn44 in South
Africa, is associated with a modest (E0.25 log) reduction in viral
load (Kiepiela et al., 2004; Leslie et al., 2010) and restricts a CD8þ
T cell epitope (KY11, codons 92–102) within a “vulnerable” Nef
region (codons 88–105) to which CD8þ T cell responses have been
associated with a protective effect (Adland et al., 2013). There are
also more Nef polymorphisms (n¼7; 65E, 71R, 93D, 102H, 108D,
176D, and 176V) associated with HLA-Bn44 than any other allele
(Supplementary Table 1), ﬁve of which are predicted to revert in
the absence of HLA-Bn44 (Adland et al., 2013). Consistent with a
cumulative effect of HLA-Bn44-driven polymorphisms on Nef
function, we observed a signiﬁcant inverse correlation between
number of such polymorphisms present and HLA-I down-regula-
tion function (Spearman's, r¼0.17 and p¼0.0042) (Fig. 5C).
Nef sequence and function in the ﬁrst year of infection: adaptation to
host environment and lack of consistent functional change
Exploratory analyses of 56 paired acute/early and 1 year post-
infection Nef clones were next performed to investigate immune-
driven evolution in Nef and functional changes over the ﬁrst year
of infection.
Firstly, sequences of matched clones were analysed to identify
common sequence changes away from or towards a particular amino
acid, that were observed in Z5 individuals, between baseline and
1 year post-infection. Five such changes were identiﬁed: X83A, X102Y,
X105K, E108D, and H116N, where X indicates any amino acid
(Table 3); all represent codons at which HLA-associated polymorph-
isms have been identiﬁed (Supplementary Table 1). Changes towards
consensus (X83A, X102Y, and X105K) may thus represent reversions of
escape mutations, suggesting ﬁtness costs for these (Matthews et al.,
2008). Indeed, reversions at codons 83 and 102 were predicted in a
recent study (Adland et al., 2013) and non-consensus amino acids at
codons 83, 102 and 105 have been statistically associated with reduced
HLA-I down-regulation previously (Mann et al., 2013; Mwimanzi et al.,
2013) and/or in the present study (Table 2). A minority of these
reversions to consensus, particularly X102Y, occurred in the presence
of the associated HLA allele, however such an occurrence has
previously been documented (Allen et al., 2004). In contrast, HLA-
associated mutations from consensus (E108D and H116N) may repre-
sent HLA-driven escape. Indeed, H116N is an HLA-Bn57 escape
mutation (Frater et al., 2007; Pillay et al., 2005) that has not been
associated with functional costs, and 108D, which associated with
decreased HLA-I down-regulation in the present and previous studies
(Mann et al., 2013), was selected four out of ﬁve times in patients
harbouring the associated HLA alleles Bn44 and Bn18. Thus, common
Nef sequence changes in the ﬁrst year of infection appear to be largely
driven by adaptation to host HLA.
Some of these common early sequence changes are expected to
increase Nef function and some are expected to decrease Nef
function. As such, it is perhaps unsurprising that in a longitudinal
analysis, no overall consistent changes in Nef-mediated CD4 or
HLA-I down-regulation functions were observed during the ﬁrst
year of infection (Wilcoxon matched-pairs signed-ranks test,
p¼0.54 and p¼0.56, respectively) (Fig. 6A and B).
Fig. 5. Relationship between HLA-associated Nef polymorphisms and Nef-
mediated HLA-I down-regulation activity. Panel A: A trend for lower HLA-I
down-regulation activity with increasing numbers of HLA-associated polymorph-
isms is shown. Panel B: A signiﬁcant negative correlation between the number of
non-consensus polymorphisms at HLA-associated codons previously associated
with reversion (Adland et al., 2013) and HLA-I down-regulation ability is shown.
Panel C: the number of HLA-B*44-associated polymorphisms present correlates
negatively with HLA-I down-regulation function. Spearman's correlation was used
to assess signiﬁcance of relationships (n¼298 for all analyses).
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Discussion
There is limited direct evidence that CD8þ T cell responses to
HIV-1 Nef impose a functional cost on the virus (Adland et al.,
2013; Mwimanzi et al., 2013; Ueno et al., 2008) and the contribu-
tion of Nef-speciﬁc CD8þ T cell responses to viral load control
remains debated (Adland et al., 2013; Kiepiela et al., 2007).
Furthermore, while gross genetic defects in Nef can contribute to
long-term non-progression (Deacon et al., 1995; Kirchhoff et al.,
1995) and attenuation of Nef functions in elite controllers have
been demonstrated (Mwimanzi et al., 2013), large population-
based studies correlating Nef functions with disease progression in
HIV-1 subtype C infection are lacking. Therefore, we investigated
the relationships between Nef-mediated CD4 and HLA-I down-
regulation functions and disease progression, as well as the
potential inﬂuence of immune-driven Nef sequence variation on
these functions, in HIV-1 subtype C infection.
As previously observed by our group (Mann et al., 2013),
Nef-mediated CD4 down-regulation function was considerably
more well-conserved than HLA-I down-regulation function in our
study, suggesting the former function as particularly important for
the virus to conserve. This is consistent with the critical role
ascribed to Nef-mediated CD4 down-regulation in mediating viral
replication and pathogenesis in humanised mouse and macaque
models in early infection, while Nef-mediated HLA-I down-
regulation is neither sufﬁcient nor required for these pathogenic
effects (Iafrate et al., 2000; Watkins et al., 2013). Despite the fairly
narrow spread of observed CD4 down-regulation values in patient
sequences (that could reduce our ability to identify signiﬁcant
correlations between this Nef function and clinical/sequence para-
meters), we observed a modest positive association (p¼0.05)
between Nef-mediated CD4 down-regulation function in early
infection and viral load set point. This result is consistent with
reports that CD4 down-regulation directly enhances viral replica-
tion through promoting budding of infectious virions (Argañaraz et
al., 2003; Lundquist et al., 2002).
On the other hand, we observed no evidence linking Nef-
mediated HLA-I down-regulation function in early infection and
viral load set point. This is consistent with studies showing a lack
of effect on SIV viral loads following knockout of HLA-I down-
regulation function in the macaque model (Swigut et al., 2004)
and a lack of correlation between this Nef function and viral loads
in a small study of HIV-1 infected individuals (Lewis et al., 2008),
indicating that this function does not directly affect viral replica-
tion. However, we observed that increased Nef-mediated HLA-I
down-regulation in early infection was linked with a subsequent
faster rate of CD4 decline. This suggests that variability in this Nef
function may affect disease progression following the initial CD4
depletion, supporting its relevance in vivo. The biological relevance
of Nef-mediated HLA-I down-regulation is also supported by
strong in vivo selection pressure to restore this function following
mutational knock-out in an SIV model (Swigut et al., 2004). As
such, the relationship between HLA-I down-regulation ability and
CD4 decline may be mediated via enhanced evasion of CD8þ T cell
Table 3
Common sequence differences (nZ5) occurring from acute/early to 1 year post-infection in 56 pairs of Nef clones.
Change Con.a HLA-associationb HLA presentc Function associationd
X83A A 83G – Bn57, Bn58:01, An03:01, An34 0/5 83G decreased HLA-I down-regulation Mann et al. (2013)
83E – Bn57
X102Y Y 102H – Bn44 3/5 102H decreased HLA-I down-regulation Mann et al. (2013)
X105K K 105R – Cn07:01 1/5 105 K increased HLA-I down-regulation Mann et al. (2013)
105 R and Q decreased HLA-I down-regulation Mann et al. (2013)
105 R decreased CD4 down-regulation Mwimanzi et al. (2013)
E108D E 108D – Bn44, Bn18 4/5 108D decreased HLA-I down-regulation Mann et al. (2013), Mwimanzi et al. (2013)
108E –Bn57:02
H116N H 116N – Bn57:03 0/5 No association
a Consensus amino acid.
b HLA alleles positively associated with an amino acid at the relevant codon at po0.05, qo0.05 (Supplementary Table 1).
c Indicates the number of individuals who expressed the relevant HLA allele (associated with variants at the codon at which the sequence change occurred).
d Statistical associations between Nef amino acid variants and Nef function as identiﬁed in previous studies.
Fig. 6. Nef functions over the ﬁrst year of infection. Panel A and B: graphs show no consistent increase or decrease in Nef-mediated CD4 (A) and HLA-I (B) down-regulation
over the ﬁrst year of infection. Functions of 56 pairs of matched Nef clones derived from acute/early infection and 1 year post-infection from the same individuals are shown.
P values from the Wilcoxon matched-pairs test are shown.
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responses by HLA-I down-regulation (Lewis et al., 2008; Swigut
et al., 2004), though why this is not additionally manifested in
higher plasma viral load remains an open question.
In this study, we found evidence that mutations selected by HLA
alleles, likely CD8þ T cell escape mutations, may reduce Nef-
mediated HLA-I down-regulation ability, but not CD4 down-
regulation function (which may be related to the highly conserved
nature of that function). The presence of certain HLA-associated
polymorphisms (102H, 105R, 108D and 199Y) was individually
signiﬁcantly associated with reduced HLA-I down-regulation. These
results extend those of a previous study demonstrating a reduction
in HLA-I down-regulation activity of Nef sequences harbouring a
combination of escape mutations in the proline-rich region (Ueno
et al., 2008). Furthermore, consistent with an inferred ﬁtness cost of
Nef HLA-associated polymorphisms associated with reversion
(Adland et al., 2013); we observed that increasing numbers of these
polymorphisms in our patient Nef sequences correlated strongly
with reduced HLA-I down-regulation.
We additionally observed that increasing numbers of muta-
tions associated with HLA-Bn44, which has been linked to a
modest reduction in viral loads (Kiepiela et al., 2004; Leslie et
al., 2010), corresponded with decreased HLA-I down-regulation.
Furthermore, we found that the number of polymorphisms within
two overlapping peptides (codons 88–105 and 134–148), to which
CD8þ T cell responses have been associated with lower viral loads
in HIV-1 infection (Adland et al., 2013), correlated signiﬁcantly and
negatively with HLA-I down-regulation function (data not shown).
These observations suggest that functional constraints may con-
tribute to the modest beneﬁt associated with HLA-Bn44 and the
beneﬁcial effects of CD8þ targeting of Nef regions 88–105 and
134–148, either directly (via ﬁtness-costly escape) or indirectly
(via sustained CD8þ T cell responses to a mutationally constrained
region i.e. delayed escape). In fact, there is much evidence that a
balance between these two factors inﬂuences viral load (Crawford
et al., 2009; Kawada et al., 2006; Wright et al., 2011). Interestingly,
we found no evidence that Nef polymorphisms commonly asso-
ciated with the protective HLA-Bn57 allele reduce Nef function,
while others have found that the number of non-canonical HLA-
Bn57-associated Nef polymorphisms particular to elite controllers,
but not those commonly associated with Bn57, correlated nega-
tively with several Nef functions in elite-controller-derived Nef
sequences (Mwimanzi et al., 2013). Nevertheless, it is possible that
HLA-Bn57 responses to Nef epitopes may contribute to slower
progression in Bn57 individuals who are not elite controllers,
considering that the Bn57-restricted Nef epitopes overlap consid-
erably with Nef regions associated with viral control (Adland et al.,
2013) and that maintenance of Nef HW9 responses was associated
with long-term non-progression in HLA-Bn57-expressing indivi-
duals (Navis et al., 2008).
Of relevance to HIV vaccine design is whether viruses in early
infection differ from those in chronic infection (which might indicate
preferential transmission of certain variants). Although Nef
sequences from early infection were marginally less similar to the
consensus C sequence, we found no features that clearly distin-
guished early from chronic Nef sequences. This is consistent with a
previous report describing similar diversity in donor and acutely-
infected recipient Nef sequences as well as a lack of optimisation of
speciﬁc Nef functions during transmission (Noviello et al., 2007). Our
longitudinal analysis of individuals from early to 1 year post-infection
revealed no consistent functional changes and that common
sequence changes occurring during this period were reversions and
selections of HLA-associated mutations. Similarly, it was previously
found that the differences between HIV sequences from early and
later infection stages largely represented reversion of mutations and
escape mutations occurring post-transmission in adaptation to the
speciﬁc host environment (Treurnicht et al., 2010). Also in line with
these ﬁndings, Noviello et al. (2007) observed that CD8þ T cell
responses appeared to be a major driver of Nef evolution during early
HIV-1 infection (Noviello et al., 2007).
In summary, this study provides evidence that variability in
Nef-mediated CD4 and HLA-I down-regulation ability among
subtype C viruses in the absence of obvious Nef genetic defects
may inﬂuence disease progression. Furthermore, immune pressure
on certain regions of Nef may result in selection of mutations that
reduce the HLA-I down-regulation function of Nef. Together with
previous studies showing clinical beneﬁt associated with CD8þ T
cell responses to particular epitopes in Nef, results support certain
Nef epitopes for consideration as components of an HIV vaccine
designed to attenuate the infection course.
Methods
Study subjects
Antiretroviral naïve patients with acute/early and chronic
HIV-1 subtype C infection were recruited from established observa-
tional cohorts and clinical trial sites in South Africa and Botswana.
Study participants with acute/early infection (n¼120) com-
prised 39 individuals from the HIV Pathogenesis Programme (HPP)
Acute Infection Cohort in Durban, South Africa (Radebe et al.,
2011; Wright et al., 2011), 31 from the Tshedimoso Study in
Botswana (Novitsky et al., 2009b, 2009c; Wright et al., 2011),
and 50 participants of the Tenofovir Gel Research for AIDS
Prevention Science (TRAPS) Cohort (in KwaZulu-Natal, South
Africa) who seroconverted in the CAPRISA 004 trial and were
from the placebo arm (Abdool Karim et al., 2010; Chopera et al.,
2013). For acute/early patients, plasma samples used were col-
lected at a median of 49 days post-infection (interquartile range
[IQR], 33–66 days post-infection). For 68 of these patients, for
whom plasma was available, an additional plasma sample col-
lected at a median of 374 days post-infection [IQR, 363–381 days
post-infection] was analysed. Viral load, CD4 count and high
resolution HLA class I data were available for all study participants
with acute/early infection. Study participants with chronic infec-
tion (n¼207) were from the Sinikithemba Cohort in Durban, South
Africa (Kiepiela et al., 2004; Mann et al., 2013; Wright et al., 2010).
Viral loads, CD4 counts, and high resolution HLA class I data were
available for these chronically infected patients as previously
described (Kiepiela et al., 2004).
Written informed consent was obtained from all study partici-
pants and ethical approval was obtained from the relevant
institutional committees.
Generation and sequencing of Nef clones
A single Nef clone per study participant was analysed. A subset of
the Nef clones studied here were previously published, including 85
from HIV-1 subtype C chronically infected individuals (Mann et al.,
2013) and 48 from individuals in acute/early infectionwhowere in the
placebo arm of the CAPRISA 004 trial (Chopera et al., 2013). Nef clones
were generated from plasma and sequenced as previously described
(Mann et al., 2013) Brieﬂy, nef was ampliﬁed from plasma-derived
HIV-1 RNA using primers containing AscI and SacII restriction enzyme
sites. The nef gene was cloned into a pSELECT-GFPzeo expression
plasmid (Invivogen, San Diego, CA, USA), which was engineered with
the corresponding restriction enzyme sites and had separate promo-
ters for the nef gene and green ﬂuorescent protein (GFP) expression.
Bulk nef polymerase chain reaction (PCR) products as well as nef clonal
sequences were sequenced using the ABI Prism Big Dye Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA).
For each study participant, a single representative Nef clone with an
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open reading frame and that clustered with the corresponding bulk
sequence in a phylogenetic tree (Guindon and Gascuel, 2003) was
selected for CD4 and HLA-I down-regulation analyses. Nef sequences
were aligned to HXB2 and stripped of insertions with respect to HXB2
using HyPhy (Kosakovsky Pond et al., 2005). All nef clones were
conﬁrmed to be HIV-1 subtype C using the recombinant identiﬁcation
program (RIP; http://www.hiv.lanl.gov/content/sequence/RIP/RIP.
html). Maximum-likelihood phylogenetic trees were constructed using
Phyml (Guindon and Gascuel, 2003) and pairwise genetic distances
from the 2004 consensus C Nef sequence (available at http://www.hiv.
lanl.gov/content/sequence/NEWALIGN/align.html) were calculated
using PATRISTIC (Fourment and Gibbs, 2006). VESPA (http://www.
hiv.lanl.gov/content/sequence/VESPA/vespa.html) was used to identify
signature differences in consensus amino acids between groups of
sequences. Sequences analysed in this study are available under
Genbank accession numbers KF208819, KF208821-3, KF208825-8,
KF208831-4, KF208836, KF208838-9, KF208842-3, KF208845,
KF208847-208853, KF208855, KF208857-208861, KF208863-5,
KF208867, KF208870, KF208872-3, KF208878-9, KF208886,
KF208889, KF208893-5, KC906734-906805, KC906991-2, and
KM262907-263141.
CD4 and HLA-I down-regulation
The CD4 and HLA-I down-regulation activities of Nef clones
were measured as previously described using a CEM-derived T cell
line expressing CD4 and engineered to stably express HLA-An02:01
(Mann et al., 2013). Brieﬂy, 300,000 cells were electroporated at
250 V and 950 μF with 4 μg Nef clone and incubated for 20–24 h,
followed by staining using APC-labelled anti-CD4 and PE-labelled
anti-HLA-An02 antibodies (BD Biosciences, San Jose, CA, USA). CD4
and HLA-I cell surface expression was measured by ﬂow cytometry
in successfully transfected (i.e GFP-expressing) cells. The CD4 and
HLA-I down-regulation activities (indicated by median ﬂuores-
cence intensity [MFI] of CD4/HLA-I expression) of Nef clones were
expressed relative to that of the positive control (SF2 Nef, set at
100% function) and the negative control (empty pSELECT plasmid,
set at 0% function), as follows: (MFInegative control–MFIpatient Nef)/
(MFInegative control – MFIpositive control). For the majority of Nef clones
(n¼297), a single transfection per Nef clone was performed and
stained in duplicate, with duplicate measurements in excellent
agreement (Spearman’s, r¼0.98 and po0.0001 for both Nef
functions). For a subset of Nef clones (n¼98), duplicate indepen-
dent transfections were performed and also correlated well
(Spearman’s, r¼0.8 and po0.0001 for CD4 down-regulation and
r¼0.9 and po0.0001 for HLA-I down-regulation). Averaged
results were analysed.
Nef expression
A minority (47 of 395, 12%) of Nef clones exhibited functions
o45% of that of the reference strain SF2 for both CD4 and HLA-I
down-regulation. For these, as well as a random selection of 78
Nef clones with functions above this threshold, Nef protein levels
were measured by Western blot as previously described (Mann et
al., 2013; Mwimanzi et al., 2011b). Brieﬂy, following transfection of
1 million CEM cells with 10 μg of Nef clones and a 24 h incubation,
cells were lysed. Following SDS-PAGE of cell lysates, proteins were
electroblotted onto a polyvinylidene diﬂuoride membrane and the
presence of Nef protein was detected using rabbit polyclonal anti-
HIV-1 Nef primary antibody (NIH AIDS Research and Reference
Reagent Program, USA) and horseradish peroxidase (HRP)-con-
jugated donkey anti-rabbit IgG secondary antibody (Amersham
Biosciences, Little Chalfont, UK). Samples that failed Nef detection
with the rabbit antibody were next probed using sheep polyclonal
anti-HIV-1 Nef primary antibody (NIBSC Center for AIDS Reagents,
UK) and HRP donkey anti-sheep IgG secondary antibody (Jackson
ImmunoResearch Europe Ltd, Suffolk, UK). Actin expression was
quantiﬁed simultaneously using monoclonal mouse anti-actin
primary antibody (Sigma, St. Louis, Missouri, USA) and HRP goat
anti-mouse secondary antibody (Jackson ImmunoResearch Europe
Ltd, Suffolk, UK). Chemiluminescence of bands was measured
using ImageQuant LAS 4000 (GE Healthcare Life Sciences, Little
Chalfont, UK). All Nef bands, including that of the SF2 control, were
quantiﬁed relative to actin expression. These values were then
normalised to that of SF2 to obtain percentage expression.
Deﬁnition of HLA-associated polymorphisms in HIV-1 subtype C Nef
HLA-associated polymorphisms are HIV amino acid variants
that are signiﬁcantly over- (or under) represented in the presence
of a particular HLA allele, as identiﬁed in statistical association
studies of linked host (HLA) and HIV sequence datasets. A
comprehensive list of HLA-associated polymorphisms was pre-
viously generated based on 1336 subtype C Nef sequences from
individuals from southern Africa using methods correcting for HIV
phylogeny, amino acid co-variation, and HLA linkage disequili-
brium (Carlson et al., 2014). HIV Nef polymorphisms in this list
that were signiﬁcantly positively associated with the expression of
a particular HLA allele at qo0.05 were deﬁned as “HLA-associated
polymorphisms” in the present analysis (Supplementary Table 1).
The total number of HLA-associated polymorphisms was
counted in each Nef clonal sequence. This was done without
taking into account the HLA alleles expressed by the patient, since
the aim of this analysis was to investigate the relationship
between number of HLA-associated polymorphisms in Nef (irre-
spective of whether they were transmitted or selected in the
present host) and Nef function.
This analysis was repeated by summing only the subset of HLA-
associated polymorphisms inferred to be “reverting” (deﬁned as
those where the absence of the restricting HLA allele is signiﬁcantly
associated with over-representation of the consensus amino acid or
under-representation of the polymorphism in statistical association
studies), suggesting that they confer a ﬁtness cost. In this analysis,
non-consensus polymorphisms at sites previously deﬁned as
“reverting” ((Adland et al., 2013), listed in Supplementary Table 1),
were counted in each Nef clonal sequence.
Statistical analysis
Nef function versus disease progression analyses
Nef-mediated CD4 and HLA-I down-regulation functions in
acute/early infection were correlated with markers of subsequent
disease progression, namely viral load set point and rate of CD4
decline, using Spearman’s correlation. Viral load set point was
calculated as the average viral load from 3 to 12 months post-
infection. Simple linear regression was used to compute the rate of
CD4 count decline for each individual over the treatment-free
follow up period, where rate of decline was deﬁned as the
estimated slope of the ﬁtted regression line (Wright et al., 2010).
Multiple linear regression was also performed to assess the
relationship between Nef functions and rate of CD4 decline while
controlling for baseline CD4 count and length of follow-up. The
nature of the CD4 decline data (a mixture of positive and negative
values) prevented the use of traditional data transformations (e.g.
square root, log, and inverse transformations). We thus limited the
analysis to CD4 decline values within the range of 50 to 50 cells/
mm3 per month since this ensured that the assumptions of
normality were sufﬁciently met and included 495% of the data.
Upon ﬁtting the ﬁnal model we tested the assumptions of
normally distributed residuals using the Shapiro–Wilk test, and
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validated that there was no relationship between the residuals and
ﬁtted values using Spearman’s correlation.
Nef sequence-function analyses
Comparisons of Nef sequence and/or Nef function were
assessed using the Mann–Whitney U-test (with the exception of
patients for whom paired early versus 1-year Nef clones were
compared, in which case the Wilcoxon matched-pairs test was
used), and Spearman’s correlation as appropriate. Signiﬁcant
differences in cohort consensus amino acids between acute/early
and chronic Nef sequences were identiﬁed using Fisher’s exact
test. Unless indicated otherwise, the signiﬁcance cut-off for all
statistical analyses was po0.05. Speciﬁc Nef amino acids (present
at a frequency of nZ5 in our dataset) associated with differences
CD4 or HLA-I down-regulation function were assessed using the
Mann–Whitney U test. Multiple comparisons were addressed
using q-values, the p-value analogue of the false-discovery rate
(Storey and Tibshirani, 2003). Here, associations with po0.05 and
qr0.4 are reported.
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